Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Molecular tumour board: Where do we stand? What’s next?

Tissue and liquid biopsies with MTB for phase 1 trial selection: Experience in the TARGET trial


29 Sep 2019


Molecular tumour board: Where do we stand? What’s next?


Clinical Research;  Targeted Therapy;  Translational Research

Tumour Site


Matthew Krebs


M.G. Krebs

Author affiliations

  • Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.